Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2015 | Phase 2/3 trial of maintenance lapatinib for HER1/2-positive metastatic bladder cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, from Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the results of a phase 2/3 trial, which evaluated if maintenance therapy with lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, after first-line chemotherapy is associated with clinical benefit in patients with HER1/2-positive metastatic transitional cell carcinoma.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.